The mutant selection window and antimicrobial resistance

被引:318
作者
Drlica, K [1 ]
机构
[1] Publ Hlth Res Inst, Newark, NJ 07103 USA
关键词
mutant selection window; antimicrobial resistance;
D O I
10.1093/jac/dkg269
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The mutant selection window is an antimicrobial concentration range extending from the minimal concentration required to block the growth of wild-type bacteria up to that required to inhibit the growth of the least susceptible, single-step mutant. The upper boundary is also called the mutant prevention concentration (MPC). Placing antimicrobial concentrations inside the window is expected to enrich resistant mutant subpopulations selectively, whereas placing concentrations above the window is expected to restrict selective enrichment. Since window dimensions are characteristic of each pathogen-antimicrobial combination, they can be linked with antimicrobial pharmacokinetics to rank compounds and dosing regimens in terms of their propensity to enrich mutant fractions of bacterial populations. For situations in which antimicrobial concentrations cannot be kept above the window, restricting the enrichment of mutants requires combination therapy.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 70 条
[41]   Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus [J].
Lu, T ;
Zhao, XL ;
Li, XY ;
Hansen, G ;
Blondeau, J ;
Drlica, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :61-64
[42]   Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties:: Action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus [J].
Lu, T ;
Zhao, XL ;
Li, XY ;
Drlica-Wagner, A ;
Wang, JY ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2703-2709
[43]  
MATHER LE, 1981, BRIT J CLIN PHARMACO, V12, P131
[44]   DRUG-RESISTANCE IN MYCOBACTERIA [J].
MITCHISON, DA .
BRITISH MEDICAL BULLETIN, 1984, 40 (01) :84-90
[45]  
Murray BE, 1997, ADV INTERNAL MED, V42, P339
[46]   Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 Central and Eastern European countries [J].
Nagai, K ;
Appelbaum, PC ;
Davies, TA ;
Kelly, LM ;
Hoellman, DB ;
Tambic Andrasevic, A ;
Drukalska, L ;
Hryniewicz, W ;
Jacobs, MR ;
Kolman, J ;
Miciuleviciene, J ;
Pana, M ;
Setchanova, L ;
Thege, MK ;
Hupkova, H ;
Trupl, J ;
Urbaskova, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :371-377
[47]  
Nakamura S, 1997, J INFECT CHEMOTHER, V3, P128, DOI 10.1007/BF02491502
[48]   Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus [J].
Ng, EY ;
Trucksis, M ;
Hooper, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1881-1888
[49]   DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae [J].
Pan, XS ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2810-2816
[50]   Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae [J].
Pan, XS ;
Ambler, J ;
Mehtar, S ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2321-2326